ReviewCurrent heart failure reports2026
Acute and Chronic Myocarditis in Men and Women.
Review in Current heart failure reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purpose of reviewAcute myocarditis (AM) shows sex-specific differences in prevalence, clinical phenotype, and outcomes. This review summarizes evidence from studies published between 2000 and 2026 reporting sex-stratified data on AM epidemiology, presentation, and prognosis to guide future research and a more personalized management. RECENT
findingsAM is more frequent in males (54-84%), who present at a younger median age than females (31-35 vs. 38-54 years). This disparity emerges from school age, peaks between 15 and 50 years, and attenuates after menopause, when female incidence increases. Men more often present with chest pain (78-91% vs. 58-78%), ST-segment elevation (35-75% vs. 8-44%), and higher troponin levels. Women more frequently present with dyspnea (29-71% vs. 9-26%), heart failure (11-55% vs. 4-47%), and a prior autoimmune disease (4-25% vs 1-10%). Contemporary registries suggest a worse early course in women, with fulminant presentation in 10-71% vs. 15-17% in men, and in-hospital mortality of 4-8% vs. 2-5%. Conversely, men appear more prone to recurrent myocarditis (3-6% vs. 2-3%). Women are overrepresented in AM associated with desmosomal gene variants (33-69%) and systemic lupus erythematosus (83-91%), whereas men predominate in eosinophilic myocarditis (67-82%) and cardiac sarcoidosis (57-70%). Current evidence supports meaningful sex-related differences in AM prevalence and prognosis, with women appearing to experience a worse early clinical course despite the overall male predominance. Larger dedicated studies are needed to improve sex-tailored risk stratification and management.
Indexed as
Identifiers
42340531What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.